Evgen Pharma Share Discussion Threads

[on target] 20/5/2021 16:33

Yes true it probably is just a turn of phrase, given they're tweeting a review of what they were doing in the last year clinical trial wise.

[moneymunch] 20/5/2021 16:15

Sorry On target, i get what you mean....maybe just a turn of phrase????

[moneymunch] 20/5/2021 16:12

What do you mean??? The trial is still on going until we hear otherwise....ie Prof Chalmers efficacy assessment will be positive or futile....the trial will be stopped if futile.....but "heavily involved" and results of the study expected later this year, suggests that Prof Chalmers efficacy data could be positive. Gl ;-)

[on target] 20/5/2021 16:09

"were" - does that mean they've stopped the study early then?

[moneymunch] 20/5/2021 16:03

Interim efficacy assessment data imminent, and potentially encouraging with study results still expected later this year!!!???? ;-)

Tayside Clinical Trials Unit
@TASC_TCTU
Replying to
@TASC_TCTU

We were also heavily involved with non-UPH COVID study STAR-COVID19 also led by @ProfJDChalmers
in @NHSTayside

We hope the results of both of these studies will be available later this year. #ICTD2021
3:55 PM · May 20, 2021·Twitter Web App

...............


Tayside Clinical Trials Unit
@TASC_TCTU
·
5m
TCTU was proud to be involved in the only multi-centre UPH COVID trial led from Scotland, STOP-COVID19 led by @ProfJDChalmers
and @NHSTayside

#ICTD2021

[moneymunch] 20/5/2021 15:54

Every chance!!! ;-)



The government is launching a taskforce that will “supercharge” the search for and development of a new generation of drugs capable of treating people with coronavirus in their own homes.

The taskforce, modelled on the team responsible for the UK’s vaccine programme, will identify and support research into promising antiviral treatments that can reduce transmission and speed up recovery from Covid-19.

It’s hoped two effective treatments – offered in tablet form – will be made available to the public as early as autumn, providing Britain with “another layer of defence” alongside the vaccines in combating possible future waves and emerging variants, said Sir Patrick Vallance.

The antivirals – a class of medication used for treating viral infections and preventing replication – will be specific to people who have tested positive for Covid or been exposed to someone carrying the virus, with the aim of keeping these individuals out of hospital.

“Our new Antivirals Taskforce will seek to develop innovative treatments you can take at home to stop COVID-19 in its tracks,” said prime minister Boris Johnson.

..............


The announcement of the formation of a COVID-19 antivirals taskforce is to be welcomed and shows ambition for the UK to be at the forefront of research into the treatment of COVID-19. This is aligned with the concept of clinical trials as a treatment option whereby patients in the UK are given the opportunity to have early access to the potential benefits of new treatments.

The RECOVERY trial and other UK studies have shown the willingness of the UK population to take part in SARS-CoV-2 related clinical trials, that may not only benefit themselves, but also lead to better treatment options for others. The antivirals taskforce follows on from the successful vaccine model which delivered well beyond expectations. In this respect it has set a high bar, but it is important to remember that drug development is an inherently risky business.

The highly ambitious target of having at least two effective treatment this year points to the taskforce supporting the re-purposing of existing drugs, and/or the latter stages of development for new targeted drugs, that are already in development. Re-purposed drugs have the advantage of a well characterized safety profile, but are less targeted than new drugs. However it takes time to establish the safety profile of new drugs.

"Nonetheless, this government-led initiative is a clear sign that the UK is open for business and is becoming an increasingly attractive place to undertake drug development."

[muddy_40] 20/5/2021 15:33

With a supercharged broccoli 🥦 pill 😉

[moneymunch] 20/5/2021 15:30

Home pill target....supercharged patient trial acceleration??? Gla :-)))

Tayside Clinical Trials Unit

@TASC_TCTU

·

55m

As part of novel trial design, TCTU is building on our incredibly successful relationship with community pharmacies, ensuring wider inclusion and participation in clinical research. Several new studies will be opening up over coming months, taking research into the community.

[the skipper] 20/5/2021 14:06

Lighter volume today but at least it seems to confirm that ther big seller is finished. Ergo,the stock should take off like a rocket on any positive news imo.

[moneymunch] 20/5/2021 13:16

Lol...., apart from his retweet today, Prof Chalmers has been relatively quiet on the Twitter front....and so might be focused elsewhere....the Tayside Clinical Trials Unit have been doing some sterling work....:-)

[on target] 20/5/2021 13:05

He's too busy tweeting.

[moneymunch] 20/5/2021 12:50

Lol...it's Professor Plumb's thumb Huw's awaiting....Tick Tock :-)

[bumpa33] 20/5/2021 12:35

Quick look in, we still waiting?



Silly me, of course we are.





Pull yer f’ing finger out Huw and give us the news...

[riggerbeautz] 20/5/2021 12:27

Don’t hurt, rather they just let us know some efficacy news mind.

[moneymunch] 20/5/2021 11:52

James D Chalmers Retweeted

Tayside Clinical Trials Unit

@TASC_TCTU

·

2h

Happy International Clinical Trials Day! To celebrate we will tweet out some of our activities over the past year across the day. #ICTD2021

[moneymunch] 19/5/2021 22:25

Everyone will be pressing BUY on positive Covid/ARDS efficacy data......The man from Dundee, says Yes!!! ...( hopefully ) ...Gla ;-)

[garth] 19/5/2021 13:21

I added AGAIN earlier. I am now full. I WILL sit on my hands. I WILL NOT press buy. (note to self)

G.

[the skipper] 19/5/2021 10:43

Sod it, I'm off fishing now so I just had another top up in my ISA before I set off and the bid has moved up to 7.40. If the seller has gone this should now move up sharply ahead of all the news which is brewing imo.

[on target] 19/5/2021 10:34

Hardly any stock offered at 7.7 either. Looks like we may have finally cleared out whatever badness has been holding us back?

[peanut100] 19/5/2021 10:30

Feels like seller cleared as stock only offered at the offer price and not below that like it has been for the last few weeks. Fingers crossed bottomed here. Topped up yesterday at 7.2p

[the skipper] 19/5/2021 10:05

Looking at the concentrated selling yesterday afternoon, followed by that 872k buy reported after the market closed and the lack of any sells this morning I am thinking that someone got wind that a forced seller had cleared. I've therefore added 29k this morning and will have another top up in a day or two if the seller does not make a reappearance.

[muddy_40] 18/5/2021 19:30

Wonder if Huw and Helen (CBO) are looking at some upfront deals.. could be eye watering.

Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset

Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact an early-stage assets out of small biotech Agenus.

The deal breaks down like this: BMS nabs full rights to the drug and will cough up $200 million right away, with around $1.36 billion in biobucks and royalty sales also on the table.

Agenus has options to run its own tests under the plan, as well as combo studies with “certain other Agenus pipeline assets,” and can co-promote AGEN1777 in the U.S. should it gain approval.

Bristol said its first targets will be “for high priority tumor indications,” including non-small cell lung cancer, with a development plan centered on combating resistance to I-O drugs, like Opdivo, and boosting efficacy through combinations. BMS already has a TIGIT in BMS-986207, although the Agenus bispecific is a slightly different form. That drug has been in trials on its own and with BMS' two checkpoint inhibitors since 2016, though it is unclear whether this new deal will see that asset pushed down the pipeline.

[dutch123] 18/5/2021 18:57

Although we are seeing tenths of a penny fluctuation, this can leap by the 10pences..and more, mm's trying to make a market.

[amaretto1] 18/5/2021 17:26

Well I've bought a few more today ....i must be wrong in my head !!We will see